IDH1 and glioblastoma: Recently, the presence of heterozygous gain-of-function mutations within the active site of isocitrate dehydrogenase-1 (IDH1), a Krebs cycle enzyme that reduces α-ketoglutarate into 2-hydroxyglutarate (2-HG), has been associated with improved clinical outcomes in GBM [44–46].